Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma
Open Access
- 19 August 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Abstract
Background: Glioma is the most common primary intracranial tumor, accounting for the vast majority of intracranial malignant tumors. Aberrant expression of RNA:5-methylcytosine(m5C) methyltransferases have recently been the focus of research relating to the occurrence and progression of tumors. However, the prognostic value of RNA:m5C methyltransferases in glioma remains unclear. This study investigated RNA: m5C methyltransferase expression and defined its clinicopathological signature and prognostic value in gliomas. Methods: We obtained the RNA-sequence and Clinicopathological data of RNA:m5C methyltransferases underlying gliomas from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) datasets. We analyzed the expression of RNA:m5C methyltransferase genes in gliomas with different clinicopathological characteristics and identified different subtypes using Consensus clustering analysis. Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) was used to annotate the function of these genes. Univariate Cox regression and the least absolute shrinkage and selection operator (LASSO) Cox regression algorithm analyses were performed to construct the risk signature. Kaplan-Meier method and Receiver operating characteristic (ROC) curves were used to assess the overall survival of glioma patients. Additionally, Cox proportional regression model analysis was developed to address the connections between the risk scores and clinical factors. Results: We revealed the differential expression of RNA:m5C methyltransferase genes in gliomas with different clinicopathological features. Consensus clustering of RNA:m5C methyltransferases identified three clusters of gliomas with different prognostic and clinicopathological features. Meanwhile, functional annotations demonstrated that RNA:m5C methyltransferases were significantly associated with the malignant progression of gliomas. Thereafter, five RNA:m5C methyltransferase genes were screened to construct a risk signature that can be used to predict not only overall survival but also clinicopathological features in gliomas. ROC curves revealed the significant prognostic ability of this signature. In addition, Multivariate Cox regression analyses indicated that the risk score was an independent prognostic factor for glioma outcome. Conclusion: We demonstrated the prognostic role of RNA:m5C methyltransferases in the initiation and progression of glioma. We have expanded on the understanding of the molecular mechanism involved, and provided a unique approach to predictive biomarkers and targeted therapy for gliomas.Keywords
Funding Information
- National Natural Science Foundation of China (81660420, 81960456)
- Natural Science Foundation of Jiangxi Province
This publication has 44 references indexed in Scilit:
- Epitranscriptomic marks: Emerging modulators of RNA virus gene expressionWIREs RNA, 2019
- Epigenetics in Neurodevelopment: Emerging Role of Circular RNAFrontiers in Cellular Neuroscience, 2019
- RNA modifications regulating cell fate in cancerNature Cell Biology, 2019
- Glioma epigenetics: From subclassification to novel treatment optionsSeminars in Cancer Biology, 2018
- Above the Epitranscriptome: RNA Modifications and Stem Cell IdentityGenes, 2018
- Detecting RNA modifications in the epitranscriptome: predict and validateNature Reviews Genetics, 2017
- Epitranscriptome sequencing technologies: decoding RNA modificationsNature Methods, 2016
- Messenger RNA modifications: Form, distribution, and functionScience, 2016
- RNA modifications: what have we learned and where are we headed?Nature Reviews Genetics, 2016
- Cancer Epigenetics: From Mechanism to TherapyCell, 2012